小细胞肺癌对tarlatamab产生耐药性后的分子亚型变化。
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer.
作者信息
Ahn Hyung-Min, Park Seog-Yun, Choi Yura, Kim Jaemin, Lee Youngjoo
机构信息
Center for Lung Cancer, National Cancer Center Hospital, Goyang, South Korea.
Department of Pathology, National Cancer Center Hospital, Goyang, South Korea.
出版信息
Drug Resist Updat. 2025 Mar;79:101198. doi: 10.1016/j.drup.2024.101198. Epub 2024 Dec 26.
PMID:39742708
Abstract
Tarlatamab, a novel bispecific T-cell engager, has demonstrated unprecedented efficacy in patients with small cell lung cancer. However, there is no known mechanism of resistance to tarlatamab. This study suggests that a transcriptional expression shift might be associated with acquired resistance to tarlatamab.
摘要
新型双特异性T细胞衔接器tarlatamab在小细胞肺癌患者中已显示出前所未有的疗效。然而，目前尚不清楚对tarlatamab产生耐药性的机制。本研究表明，转录表达变化可能与对tarlatamab的获得性耐药有关。
Zotero 插件